Yesterday, Coherus announced that CHS-1420, its proposed biosimilar of Humira^® (adalimumab), met the primary endpoint in a clinical pharmacokinetic (PK) bioequivalence study that compared CHS-1420 to Humira. According to Coherus, the study showed clinical PK similarity on all prospectively defined PK endpoints. It was reported that both agents were well tolerated and that no differential safety findings were observed.

Stay tuned to Big Molecule Watch for more updates